chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Lethargy, Pyrexia
Clinical narrative: Fever; Lethargic; Tired after 1st dose/Tired after 2nd dose; This spontaneous case was reported by a patient family member or friend and describes the occurrence of FATIGUE (Tired after 1st dose/Tired after 2nd dose), PYREXIA (Fever) and LETHARGY (Lethargic) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. UNKNOWN) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure and Hemochromatosis.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 2 dosage form. On 04-Mar-2021, the patient experienced FATIGUE (Tired after 1st dose/Tired after 2nd dose). On 01-Apr-2021, the patient experienced PYREXIA (Fever) and LETHARGY (Lethargic). On 05-Mar-2021, FATIGUE (Tired after 1st dose/Tired after 2nd dose) had resolved. On 02-Apr-2021, PYREXIA (Fever) and LETHARGY (Lethargic) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.       Reporter did not allow further contact
Age: 71.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Pain in extremity, Peripheral swelling
Clinical narrative: Arm red; Arm swollen; Hurt arm; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Arm red), PERIPHERAL SWELLING (Arm swollen) and PAIN IN EXTREMITY (Hurt arm) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Congestive heart failure and Diabetic.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jun-2021, the patient experienced ERYTHEMA (Arm red), PERIPHERAL SWELLING (Arm swollen) and PAIN IN EXTREMITY (Hurt arm). At the time of the report, ERYTHEMA (Arm red), PERIPHERAL SWELLING (Arm swollen) and PAIN IN EXTREMITY (Hurt arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided by the reporter.  Treatment information was not provided.
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Fatigue, Lethargy, Pyrexia
Clinical narrative: Lethargic; Fever 102.7 degrees Fahrenheit; Tired after 2nd dose; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (Lethargic), PYREXIA (Fever 102.7 degrees Fahrenheit) and FATIGUE (Tired after 2nd dose) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension and Hemochromatosis.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Apr-2021, the patient experienced LETHARGY (Lethargic), PYREXIA (Fever 102.7 degrees Fahrenheit) and FATIGUE (Tired after 2nd dose). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) ongoing since an unknown date at an unspecified dose and frequency. On 02-Apr-2021, LETHARGY (Lethargic), PYREXIA (Fever 102.7 degrees Fahrenheit) and FATIGUE (Tired after 2nd dose) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 01-Apr-2021, Body temperature: 102.7 (High) 102.7 degrees Fahrenheit.         Relevant concomitant medications included unspecified medications for blood pressure and Hemochromatosis.   This case was linked to MOD-2021-218679 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Dizziness, Feeling drunk
Clinical narrative: dizzy; feel like im slightly drunk; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizzy) and FEELING DRUNK (feel like im slightly drunk) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIZZINESS (dizzy) and FEELING DRUNK (feel like im slightly drunk). At the time of the report, DIZZINESS (dizzy) and FEELING DRUNK (feel like im slightly drunk) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications reported. No treatment information was provided.   Reporter did not allow further contact
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Myalgia
Clinical narrative: arm was just a little sore after first dose; This spontaneous case was reported by a patient (subsequently medically confirmed) and describes the occurrence of MYALGIA (arm was just a little sore after first dose) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045ABIA) for COVID-19 vaccination.     Concomitant products included PARACETAMOL (TYLENOL) for Allergy.    On 10-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, the patient experienced MYALGIA (arm was just a little sore after first dose). At the time of the report, MYALGIA (arm was just a little sore after first dose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient took medications for stroke as concomitant product. No Treatment were reported.
Sex: M
Vaccine: COVID19
Symptoms: Pruritus, Rash
Clinical narrative: Itchy all over; Developed a rash on his posterior neck area, top of both shoulders, all over his back, and torso; This spontaneous case was reported by a patient and describes the occurrence of PRURITUS (Itchy all over) and RASH (Developed a rash on his posterior neck area, top of both shoulders, all over his back, and torso) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 018B21A and 011A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 05-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 07-Jun-2021, the patient experienced PRURITUS (Itchy all over) and RASH (Developed a rash on his posterior neck area, top of both shoulders, all over his back, and torso). At the time of the report, PRURITUS (Itchy all over) and RASH (Developed a rash on his posterior neck area, top of both shoulders, all over his back, and torso) outcome was unknown.            No concomitant medications are provided .  The patient had been doing fine for the past 2 months or so.  No treatment medications are provided .
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Pruritus, Rash erythematous
Clinical narrative: Develop a circular red rash on the arm of the vaccination; Itchy area on arm; Pain on the arm of the vaccination; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Develop a circular red rash on the arm of the vaccination), PRURITUS (Itchy area on arm) and PAIN IN EXTREMITY (Pain on the arm of the vaccination) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 024C21A) for COVID-19 vaccination.     No medical history and concomitant drug information provided by reporter.     On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-May-2021, the patient experienced RASH ERYTHEMATOUS (Develop a circular red rash on the arm of the vaccination), PRURITUS (Itchy area on arm) and PAIN IN EXTREMITY (Pain on the arm of the vaccination). At the time of the report, RASH ERYTHEMATOUS (Develop a circular red rash on the arm of the vaccination), PRURITUS (Itchy area on arm) and PAIN IN EXTREMITY (Pain on the arm of the vaccination) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       treatment medications were not reported no concomitant medications were reported  for mRNA-1273 (Moderna COVID-19 Vaccine) (intramuscular), the reporter did not provide any causality assessment.     Most recent FOLLOW-UP information incorporated above includes: On 12-Jul-2021: Follow-up received on 12-jul-2021contains no significant information
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: Full body rash I had after the vaccine; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Full body rash I had after the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced RASH (Full body rash I had after the vaccine). At the time of the report, RASH (Full body rash I had after the vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant products reported  No treatment medications were provided.   Most recent FOLLOW-UP information incorporated above includes: On 14-Jun-2021: Follow-up information received on 14-JUN-2021: No new information received On 07-Jul-2021: non Significant Follow-up
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: severe pins and needles sensation in both hands, feet and legs; This spontaneous case was reported by a physician and describes the occurrence of PARAESTHESIA (severe pins and needles sensation in both hands, feet and legs) in a 37-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027C21A) for COVID-19 vaccination.     Concurrent medical conditions included Allergy (spring allergy). Concomitant products included VITAMIN D NOS for Vitamin D deficiency.    On 21-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-May-2021, the patient experienced PARAESTHESIA (severe pins and needles sensation in both hands, feet and legs). The patient was treated with PARACETAMOL (TYLENOL) for Pins and needles, at a dose of 1 dosage form. At the time of the report, PARAESTHESIA (severe pins and needles sensation in both hands, feet and legs) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: Follow up received on 13 Jul 2021 and it contains patient demographics and medical history updated.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Breast swelling, Cough, Malaise, Rhinorrhoea, Vaccination site pain
Clinical narrative: not feeling too good the last few days; lots of coughing; Lotsof drainage; arm was sore; left breast was swollen right after the second dose and it is still a bit swollen; This spontaneous case was reported by a consumer and describes the occurrence of BREAST SWELLING (left breast was swollen right after the second dose and it is still a bit swollen), MALAISE (not feeling too good the last few days), COUGH (lots of coughing), RHINORRHOEA (Lots of drainage) and VACCINATION SITE PAIN (arm was sore) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 072B21A) for COVID-19 vaccination.     Concurrent medical conditions included Stroke. Concomitant products included PARACETAMOL (TYLENOL) for an unknown indication.    On 08-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 08-May-2021, the patient experienced BREAST SWELLING (left breast was swollen right after the second dose and it is still a bit swollen) and VACCINATION SITE PAIN (arm was sore). On an unknown date, the patient experienced MALAISE (not feeling too good the last few days). an unknown date, the patient experienced COUGH (lots of coughing) and RHINORRHOEA (Lotsof drainage). At the time of the report, BREAST SWELLING (left breast was swollen right after the second dose and it is still a bit swollen), MALAISE (not feeling too good the last few days), COUGH (lots of coughing) and RHINORRHOEA (Lotsof drainage) outcome was unknown and VACCINATION SITE PAIN (arm was sore) had not resolved.            Patient took unspecified medications for stroke. Other concomitant medicines include 4 Allergy medications  No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site swelling
Clinical narrative: under her injection arm about two weeks after her first dose; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE SWELLING (under her injection arm about two weeks after her first dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced VACCINATION SITE SWELLING (under her injection arm about two weeks after her first dose). At the time of the report, VACCINATION SITE SWELLING (under her injection arm about two weeks after her first dose) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications reported by investigator No treatment medications provided by the reporter.
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Dyspnoea, Fatigue, Feeling abnormal, Oral herpes
Clinical narrative: Sleepy all the time; Fever blisters; Arms swollen for seven days; Shortness of breath; Has no energy/she wants to do is lay down; Feels like crap; Has been tired / extremely fatigued; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (Sleepy all the time), ORAL HERPES (Fever blisters), PERIPHERAL SWELLING (Arms swollen for seven days), DYSPNOEA (Shortness of breath) and ASTHENIA (Has no energy/she wants to do is lay down) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) and OXYCODONE for an unknown indication.   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (Sleepy all the time), ORAL HERPES (Fever blisters), PERIPHERAL SWELLING (Arms swollen for seven days), DYSPNOEA (Shortness of breath), ASTHENIA (Has no energy/she wants to do is lay down), FEELING ABNORMAL (Feels like crap) and FATIGUE (Has been tired / extremely fatigued). At the time of the report, SOMNOLENCE (Sleepy all the time), ORAL HERPES (Fever blisters), DYSPNOEA (Shortness of breath), ASTHENIA (Has no energy/she wants to do is lay down), FEELING ABNORMAL (Feels like crap) and FATIGUE (Has been tired / extremely fatigued) outcome was unknown and PERIPHERAL SWELLING (Arms swollen for seven days) had resolved.            Additional concomitant medications was thyroid medication.  Laboratory detail was thyroid numbers are messed up.  No treatment information was provided.   This case was linked to MOD-2021-218849 (Patient Link).
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling, Somnolence
Clinical narrative: Sleepy all the time; Fever blisters; Arms swollen for seven days; Shortness of breath; Has no energy/she wants to do is lay down; Feels like crap; Has been tired / extremely fatigued; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (Sleepy all the time), ORAL HERPES (Fever blisters), PERIPHERAL SWELLING (Arms swollen for seven days), DYSPNOEA (Shortness of breath) and ASTHENIA (Has no energy/she wants to do is lay down) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21a) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No medical history was provided by the reporter.  Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) and OXYCODONE for an unknown indication.   On 26-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SOMNOLENCE (Sleepy all the time), ORAL HERPES (Fever blisters), PERIPHERAL SWELLING (Arms swollen for seven days), DYSPNOEA (Shortness of breath), ASTHENIA (Has no energy/she wants to do is lay down), FEELING ABNORMAL (Feels like crap) and FATIGUE (Has been tired / extremely fatigued). At the time of the report, SOMNOLENCE (Sleepy all the time), ORAL HERPES (Fever blisters), DYSPNOEA (Shortness of breath), ASTHENIA (Has no energy/she wants to do is lay down), FEELING ABNORMAL (Feels like crap) and FATIGUE (Has been tired / extremely fatigued) outcome was unknown and PERIPHERAL SWELLING (Arms swollen for seven days) had resolved.            Additional concomitant medications was thyroid medication.  Laboratory detail was thyroid numbers are messed up.  No treatment information was provided.   This case was linked to MOD-2021-218849 (Patient Link).
Sex: U
Vaccine: COVID19
Symptoms: Exposure to SARS-CoV-2, Malaise
Clinical narrative: exposed to covid; not feeling well; This spontaneous case was reported by a consumer and describes the occurrence of EXPOSURE TO SARS-COV-2 (exposed to covid) and MALAISE (not feeling well) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced EXPOSURE TO SARS-COV-2 (exposed to covid) and MALAISE (not feeling well). At the time of the report, EXPOSURE TO SARS-COV-2 (exposed to covid) and MALAISE (not feeling well) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 13.0
Sex: M
Vaccine: COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Administered the Moderna COVID-19 vaccine to a 13 year old patient; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Administered the Moderna COVID-19 vaccine to a 13 year old patient) in a 13-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 12-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient received first dose of TOZINAMERAN (PFIZER BIONTECH COVID-19 VACCINE) (Intramuscular) 1 dosage form. On 12-Jun-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Administered the Moderna COVID-19 vaccine to a 13 year old patient). On 12-Jun-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Administered the Moderna COVID-19 vaccine to a 13 year old patient) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   ? No treatment information was provided.  Action taken with mRNA-1273 in response to the event was not applicable.
Sex: F
Vaccine: COVID19
Symptoms: Swelling
Clinical narrative: Swelling under injection arm; This spontaneous case was reported by a patient and describes the occurrence of SWELLING (Swelling under injection arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SWELLING (Swelling under injection arm). At the time of the report, SWELLING (Swelling under injection arm) had not resolved.            Concomitant product use was not provided by the reporter.  Patient had swelling under her injection arm about two weeks after her first dose.The swelling went down just a little before receiving her second dose on 14 May2021. Patient still had swelling under her same arm of injection.  Treatment information was not provided by the reporter.   This case was linked to MOD-2021-218715 (Patient Link).   Reporter did not allow further contact
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Myalgia, Nausea, Pyrexia, Vomiting
Clinical narrative: Nausea; Headache; Back spasms; Vomiting after second dose; Fever of 101 after second dose; This spontaneous case was reported by a consumer and describes the occurrence of VOMITING (Vomiting after second dose), PYREXIA (Fever of 101 after second dose), HEADACHE (Headache), MYALGIA (Back spasms) and NAUSEA (Nausea) in a 33-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022C21A and 0025C21A) for COVID-19 vaccination.     No past medical history were reported.    On 12-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Jun-2021, the patient experienced VOMITING (Vomiting after second dose) and PYREXIA (Fever of 101 after second dose). On 11-Jun-2021, the patient experienced HEADACHE (Headache) and MYALGIA (Back spasms). On an unknown date, the patient experienced NAUSEA (Nausea). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, VOMITING (Vomiting after second dose), PYREXIA (Fever of 101 after second dose), HEADACHE (Headache), MYALGIA (Back spasms) and NAUSEA (Nausea) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Action taken with mRNA-1273 in response to the event was not applicable.  No Concomitant medication were reported.
Sex: U
Vaccine: COVID19
Symptoms: Headache, Myalgia
Clinical narrative: Dcfore arm; Headache; This spontaneous case was reported by a consumer and describes the occurrence of MYALGIA (Dcfore arm) and HEADACHE (Headache) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA (Dcfore arm) and HEADACHE (Headache). At the time of the report, MYALGIA (Dcfore arm) and HEADACHE (Headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication reported. No treatment information was provided.; Sender's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Inappropriate schedule of product administration, Magnetic resonance imaging, Pyrexia
Clinical narrative: second dose scheduled on day 90 (June15); fever (post surgery); Chills (post surgery); This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose scheduled on day 90 (June15)), PYREXIA (fever (post surgery)) and CHILLS (Chills (post surgery)) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination.     The patient's past medical history included Surgery (Hospitalization for cancer surgery) from 07-Apr-2021 to 07-May-2021. Concurrent medical conditions included Cancer since 2018. Concomitant products included SERTRALINE HYDROCHLORIDE (ZOLOFT) and LACOSAMIDE (VIMPAT) for an unknown indication.    On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 21-Apr-2021, the patient experienced PYREXIA (fever (post surgery)) and CHILLS (Chills (post surgery)). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose scheduled on day 90 (June15)). On 28-Apr-2021, PYREXIA (fever (post surgery)) and CHILLS (Chills (post surgery)) had resolved. At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (second dose scheduled on day 90 (June15)) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 22-Mar-2021, Magnetic resonance imaging: abnormal (abnormal) scheduled surgery for fast-growing tumor..     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient was hospitalized for cancer surgery on 07-APR-2021 and discharged on 07-MAY-2021  Treatment information included, antibiotics post surgery for two weeks was provided.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Product dose omission issue, Vaccination site pain
Clinical narrative: Patient want to take the second dose of vaccine after 67 days; Sore arm; This spontaneous case was reported by a patient and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (Patient want to take the second dose of vaccine after 67 days) and VACCINATION SITE PAIN (Sore arm) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Fecal incontinence and Social anxiety disorder.    On 15-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 15-Apr-2021, the patient experienced VACCINATION SITE PAIN (Sore arm). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient want to take the second dose of vaccine after 67 days). At the time of the report, PRODUCT DOSE OMISSION ISSUE (Patient want to take the second dose of vaccine after 67 days) and VACCINATION SITE PAIN (Sore arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication and treatment information were not reported.
Sex: M
Vaccine: COVID19
Symptoms: Product dose omission issue
Clinical narrative: first dose>35 days ago; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (first dose>35 days ago) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     No Medical History information was reported.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (first dose>35 days ago). At the time of the report, PRODUCT DOSE OMISSION ISSUE (first dose>35 days ago) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       The patient received his first dose of Moderna COVID19 Vaccine on 24 Mar 2021. He did not received his second dose.   Most recent FOLLOW-UP information incorporated above includes: On 30-Jul-2021: Follow-up received and contains no new information.
Sex: U
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: feeling numb; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (feeling numb) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (feeling numb). At the time of the report, HYPOAESTHESIA (feeling numb) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Relevant concomitant medications was reported.  Treatment information was not provided.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Blood glucose, Hypersensitivity, Vaccination site erythema, Vaccination site pain, Vaccination site swelling
Clinical narrative: Hypersensitivity at the site; Red; Tender; Site was swollen; This spontaneous case was reported by an other health care professional and describes the occurrence of HYPERSENSITIVITY (Hypersensitivity at the site), VACCINATION SITE ERYTHEMA (Red), VACCINATION SITE PAIN (Tender) and VACCINATION SITE SWELLING (Site was swollen) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination.     Concurrent medical conditions included Type I diabetes mellitus. Concomitant products included LEVOTHYROXINE, LISINOPRIL and SIMVASTATIN for an unknown indication.    On 27-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced HYPERSENSITIVITY (Hypersensitivity at the site), VACCINATION SITE ERYTHEMA (Red), VACCINATION SITE PAIN (Tender) and VACCINATION SITE SWELLING (Site was swollen). The patient was treated with INSULIN ASPART (NOVOLOG) ongoing since an unknown date for Type I diabetes mellitus, at a dose of 6 unit at bedtime. At the time of the report, HYPERSENSITIVITY (Hypersensitivity at the site), VACCINATION SITE ERYTHEMA (Red), VACCINATION SITE PAIN (Tender) and VACCINATION SITE SWELLING (Site was swollen) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood glucose: 50-250 mg/dl (abnormal) Blood sugars with  wide fluctuations of lows of 50's and highs of 250 mg/dl.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Additional treatment included ice applied on the vaccination site.   Due to the fluctuations in blood glucose post-COVID-19 vaccination, insulin treatment varied from  the regular dose of 6 units up to 24 units nightly.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Dose administered 24 hours after first puncture; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered 24 hours after first puncture) in a 32-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered 24 hours after first puncture). On 11-Jun-2021, EXPIRED PRODUCT ADMINISTERED (Dose administered 24 hours after first puncture) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not reported. Treatment details not provided. Pharmacist stated that a vial of Moderna COVID-19 Vaccine was first punctured on 10Jun2021 at around 11 am and got a dose from that vial on 11Jun2021 at around 11 am, more than 12 hours after the first punctured. Pharmacist provided consent for safety team to contact patient on her phone number.
Sex: U
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Body temperature is above 103 degrees Fahrenheit; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Body temperature is above 103 degrees Fahrenheit) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced PYREXIA (Body temperature is above 103 degrees Fahrenheit). At the time of the report, PYREXIA (Body temperature is above 103 degrees Fahrenheit) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact
Sex: U
Vaccine: COVID19
Symptoms: Headache, Myalgia
Clinical narrative: This spontaneous case reported by a consumer, describes the occurrence of headaches (intense like brain was on fire) and myalgia (body aches) in a patient, of an unknown age and gender, who received mRNA-1273 (Moderna COVID-19 vaccine) for COVID-19 immunization. No medical history reported. On Jun 9, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), unknown route; 1 dosage form. On an unknown date, patient experienced headaches (intense like brain was on fire) and myalgia (body aches). At the time of the report, headaches (intense like brain was on fire) and myalgia (body aches) outcome: unknown. The action taken with mRNA-1273 (Moderna COVID-19 vaccine): unknown. No concomitant medication or treatment information provided.
Sex: U
Vaccine: COVID19
Symptoms: Dizziness, Vision blurred
Clinical narrative: 3mins after receiving my first dose of moderna I experienced blurry vision and dizziness; 3mins after receiving my first dose of moderna I experienced blurry vision and dizziness; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 11-Jun-2021 and was forwarded to Moderna on 11-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of VISION BLURRED (3mins after receiving my first dose of moderna I experienced blurry vision and dizziness) and DIZZINESS (3mins after receiving my first dose of moderna I experienced blurry vision and dizziness) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VISION BLURRED (3mins after receiving my first dose of moderna I experienced blurry vision and dizziness) and DIZZINESS (3mins after receiving my first dose of moderna I experienced blurry vision and dizziness). At the time of the report, VISION BLURRED (3mins after receiving my first dose of moderna I experienced blurry vision and dizziness) and DIZZINESS (3mins after receiving my first dose of moderna I experienced blurry vision and dizziness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided by the reporter. Treatment information was not provided.
Age: 62.0
Sex: M
Vaccine: COVID19
Symptoms: Expired product administered
Clinical narrative: Patient received expired Moderna Covid-19 vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received expired Moderna Covid-19 vaccine) in a 62-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 028A21A) for COVID-19 vaccination.     Concomitant products included HYDROCHLOROTHIAZIDE, LISINOPRIL (LISINOPRIL/HCTZ) for Hypertension.   On 18-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-May-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received expired Moderna Covid-19 vaccine). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received expired Moderna Covid-19 vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No treatment medications were reported.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jun-2021: Follow up information received on 22-Jun-2021 and included concomitant medication details were added, Suspect vaccine (2nd dose) route of administration was updated.
Age: 44.0
Sex: F
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: 43 days since the first dose; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (43 days since the first dose) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 045B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 29-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Jun-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (43 days since the first dose). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (43 days since the first dose) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided by the reporter.
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: Limb discomfort, Peripheral swelling
Clinical narrative: Feet and legs have been swollen; After the 1st dose she had issues with her right foot; This spontaneous case was reported by a consumer and describes the occurrence of LIMB DISCOMFORT (After the 1st dose she had issues with her right foot) and PERIPHERAL SWELLING (Feet and legs have been swollen) in a 78-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Mar-2021, the patient experienced LIMB DISCOMFORT (After the 1st dose she had issues with her right foot). On an unknown date, the patient experienced PERIPHERAL SWELLING (Feet and legs have been swollen). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, LIMB DISCOMFORT (After the 1st dose she had issues with her right foot) and PERIPHERAL SWELLING (Feet and legs have been swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  Treatment information include 2 different antibiotics.   This case was linked to MOD-2021-218760 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 02-Jul-2021: Follow up received by safety 02-Jul-2021 included a TCR: HCP details provided.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Pain in extremity
Clinical narrative: Sore arm and her arm hurt; Chills; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Sore arm and her arm hurt) and CHILLS (Chills) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030A21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes, Blood pressure and Cholesterol. Concomitant products included HYDROCHLOROTHIAZIDE, TRIAMTERENE (TRIAMTERENE/HCTZ) for Blood pressure management, ATORVASTATIN for Cholesterol, METFORMIN, GLIPIZIDE and SITAGLIPTIN PHOSPHATE (JANUVIA) for Diabetes.    On 03-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Sore arm and her arm hurt) and CHILLS (Chills). The patient was treated with IBUPROFEN (MOTRIN [IBUPROFEN]) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (Sore arm and her arm hurt) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       This case was linked to MOD-2021-218784 (Patient Link).
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Dyspnoea
Clinical narrative: Difficulty breathing; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Difficulty breathing) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023C214) for COVID-19 vaccination.     Concomitant products included APIXABAN (ELIQUIS), FLUTICASONE PROPIONATE (PROAIR [FLUTICASONE PROPIONATE]) and ERGOCALCIFEROL (VITAMIN D2) for an unknown indication.    On 24-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-May-2021, the patient experienced DYSPNOEA (Difficulty breathing). The patient was treated with OXYGEN on 25-May-2021 for Difficulty breathing, at an unspecified dose and frequency. At the time of the report, DYSPNOEA (Difficulty breathing) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Inappropriate schedule of product administration
Clinical narrative: can take the second dose of the Moderna Covid19 vaccine after the 28 days mark, because they missed their appointment; Felt chills; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Felt chills) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (can take the second dose of the Moderna Covid19 vaccine after the 28 days mark, because they missed their appointment) in a 59-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047a21a) for COVID-19 vaccination.     No Medical History information was reported.    On 14-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-May-2021, the patient experienced CHILLS (Felt chills). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (can take the second dose of the Moderna Covid19 vaccine after the 28 days mark, because they missed their appointment). At the time of the report, CHILLS (Felt chills) outcome was unknown and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (can take the second dose of the Moderna Covid19 vaccine after the 28 days mark, because they missed their appointment) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication was reported. Treatment information was not provided.
Sex: U
Vaccine: COVID19
Symptoms: Nail ridging
Clinical narrative: Beau lines; This spontaneous case was reported by a consumer and describes the occurrence of NAIL RIDGING (Beau lines) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NAIL RIDGING (Beau lines). At the time of the report, NAIL RIDGING (Beau lines) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's concomitant medication was not reported.  No treatment medication was reported.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: Arthralgia, Bursa disorder, Condition aggravated, Pain in extremity, Swelling
Clinical narrative: Bursa; neck swelling and pain in arm become worse.; Pain in arm; shoulder area hurting; my neck area around is swollen/swollen neck; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of BURSA DISORDER (Bursa), SWELLING (my neck area around is swollen/swollen neck), CONDITION AGGRAVATED (neck swelling and pain in arm become worse.), PAIN IN EXTREMITY (Pain in arm) and ARTHRALGIA (shoulder area hurting) in a 51-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 08-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-May-2021, the patient experienced SWELLING (my neck area around is swollen/swollen neck), PAIN IN EXTREMITY (Pain in arm) and ARTHRALGIA (shoulder area hurting). On 16-May-2021, the patient experienced CONDITION AGGRAVATED (neck swelling and pain in arm become worse.). On an unknown date, the patient experienced BURSA DISORDER (Bursa). The patient was treated with Physical therapy for Bursa disorder. At the time of the report, BURSA DISORDER (Bursa), SWELLING (my neck area around is swollen/swollen neck), CONDITION AGGRAVATED (neck swelling and pain in arm become worse.), PAIN IN EXTREMITY (Pain in arm) and ARTHRALGIA (shoulder area hurting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication information was provided.   CT scan and blood clot test was performed but results were not provided.  on 16-May-2021 the neck swelling and pain in arm became worse.   Treatment medication includes Steroids   Most recent FOLLOW-UP information incorporated above includes: On 11-Jun-2021: Follow-up received Patient demographics and clinical course updated, New events added, event terms updated. On 31-Jul-2021: Non signi ficant followup; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.